High-throughput protein crystallography and drug discovery

被引:55
|
作者
Tickle, I [1 ]
Sharff, A [1 ]
Vinkovic, M [1 ]
Yon, J [1 ]
Jhoti, H [1 ]
机构
[1] Astex Technol Ltd, Cambridge CB4 0QA, England
关键词
D O I
10.1039/b314510g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Single crystal X-ray diffraction is the technique of choice for studying the interactions of small organic molecules with proteins by determining their three-dimensional structures; however the requirement for highly purified protein and lack of process automation have traditionally limited its use in this field. Despite these shortcomings, the use of crystal structures of therapeutically relevant drug targets in pharmaceutical research has increased significantly over the last decade. The application of structure-based drug design has resulted in several marketed drugs and is now an established discipline in most pharmaceutical companies. Furthermore, the recently published full genome sequences of Homo sapiens and a number of micro-organisms have provided a plethora of new potential drug targets that could be utilised in structure-based drug design programs. In order to take maximum advantage of this explosion of information, techniques have been developed to automate and speed up the various procedures required to obtain protein crystals of suitable quality, to collect and process the raw X-ray diffraction data into usable structural information, and to use three-dimensional protein structure as a basis for drug discovery and lead optimisation. This tutorial review covers the various technologies involved in the process pipeline for high-throughput protein crystallography as it is currently being applied to drug discovery. It is aimed at synthetic and computational chemists, as well as structural biologists, in both academia and industry, who are interested in structure-based drug design.
引用
收藏
页码:558 / 565
页数:8
相关论文
共 50 条
  • [1] High-throughput crystallography to enhance drug discovery
    Sharff, A
    Jhoti, H
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2003, 7 (03) : 340 - 345
  • [2] High-throughput crystallography for lead discovery in drug design
    Tom L. Blundell
    Harren Jhoti
    Chris Abell
    Nature Reviews Drug Discovery, 2002, 1 : 45 - 54
  • [3] High-throughput crystallography for lead discovery in drug design
    Blundell, TL
    Jhoti, H
    Abell, C
    NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) : 45 - 54
  • [4] High-throughput X-ray crystallography for drug discovery
    Blundell, TL
    Abell, C
    Cleasby, A
    Hartshorn, MJ
    Tickle, IJ
    Parasini, E
    Jhoti, H
    DRUG DESIGN: CUTTING EDGE APPROACHES, 2002, (279): : 53 - 59
  • [5] High-throughput X-ray crystallography for drug discovery
    Blundell, TL
    Patel, S
    CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (05) : 490 - 496
  • [6] The genesis of high-throughput structure-based drug discovery using protein crystallography
    Kuhn, P
    Wilson, K
    Patch, MG
    Stevens, RC
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (05) : 704 - 710
  • [7] Rapid-access, high-throughput synchrotron crystallography for drug discovery
    Wasserman, Stephen R.
    Koss, John W.
    Sojitra, Sonal T.
    Morisco, Laura L.
    Burley, Stephen K.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (05) : 261 - 267
  • [8] Crystallography companion agent for high-throughput materials discovery
    Maffettone, Phillip M.
    Banko, Lars
    Cui, Peng
    Lysogorskiy, Yury
    Little, Marc A.
    Olds, Daniel
    Ludwig, Alfred
    Cooper, Andrew, I
    NATURE COMPUTATIONAL SCIENCE, 2021, 1 (04): : 290 - 297
  • [9] Crystallography companion agent for high-throughput materials discovery
    Phillip M. Maffettone
    Lars Banko
    Peng Cui
    Yury Lysogorskiy
    Marc A. Little
    Daniel Olds
    Alfred Ludwig
    Andrew I. Cooper
    Nature Computational Science, 2021, 1 : 290 - 297
  • [10] High-throughput structural biology in drug discovery: Protein kinases
    Stout, TJ
    Foster, PG
    Matthews, DJ
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (10) : 1069 - 1082